UBS analyst AJ Rice upgraded Aveanna (AVAH) to Neutral from Sell with a price target of $8, up from $6.75. The company’s leverage trajectory has more visibility and the impacts of the interest rate swaps/caps are better understood, the analyst tells investors in a research note. The outsized earnings performance year-to-date creates a trajectory that allows for the company to accelerate the path forward to getting to a reasonable leverage ratio, UBS says.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVAH:
- Aveanna upgraded to Overweight from Equal Weight at Barclays
- Aveanna Healthcare’s Earnings Call Highlights Growth and Optimism
- Aveanna price target raised to $6.75 from $5 at UBS
- Aveanna upgraded to Outperform from Market Perform at Raymond James
- Aveanna Healthcare Highlights Strong Financial Performance